Dynamics of CD86 Expression on Allergic Inflammation - New Insights

Author(s): Celso Pereira, Beatriz Tavares, Graca Loureiro, Artur Paiva, Ana Henriques, Margarida Abrantes, Daniel Machado, Filomena Botelho, Manuel F. Baganha.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 3 , Issue 2 , 2009

Become EABM
Become Reviewer

Abstract:

CD86 is a well-known costimulatory molecule in its interaction with CD28 and/or CTLA present on T cells, and is essential for full activation of naive T-cell and subsequent differentiation. Usually the B7 molecules are expressed mainly on APCs and B cells and in specific conditions on other activated cells. These costimulatory molecules are involved in the development of allergic inflammation and airways hyperreactivity (AHR) in allergen-challenged mice. Activated T cells, CD4+CD25+, express CD86 in the first 60 minutes after the specific inhalatory exposure. These T cells can be relevant in IgE mediated allergic reaction possibly by an autocrine costimulation via CD28/CTLA activation pathway. The blockage of the expression of CD86 could be a potential therapeutical target to reduce the magnitude or the progression of the allergic reaction. The review article also discussed relevant patents.

Keywords: Allergic inflammation, CD86, CD80, costimulatory molecules

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 2
Year: 2009
Page: [128 - 131]
Pages: 4
DOI: 10.2174/187221309788489751
Price: $58

Article Metrics

PDF: 5